Lv7
5440 积分 2023-02-21 加入
盐酸环丙沙星合成与结晶过程的研究
3个月前
已完结
麝香系统溶液结晶溶剂选择的研究
3个月前
已完结
FIGO-Ⅰ期卵巢透明细胞癌患者预后分析
8个月前
已完结
Ⅰ期卵巢透明细胞癌患者临床病理特点及预后分析——北京协和医院12年临床资料回顾性分析
8个月前
已完结
基于GC-MS探讨肝脏再生代谢变化规律及相关代谢标志物的研究
9个月前
已完结
Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors
1年前
已完结
Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors
1年前
已完结
The synthesis and evaluation of sulfonamide derivatives target EGFR790M/L858R mutations and ALK rearrangement as anticancer agents
1年前
已完结
Identification of highly potent 2,4‐diarylaminopyrimidine analogs of a typical piperidinyl‐4‐ol moiety as promising antitumor ALK inhibitors
1年前
已完结
Abstract 2771: KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death
2天前
已采纳
Data from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
8天前
已采纳
Abstract B123: Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects
10天前
已采纳
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies
13天前
已采纳
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies
13天前
已驳回
Abstract 830: ISU104, a fully human antibody targeting a specific epitope on the ErbB3, displays potent inhibition of tumor growth in multiple xenograft tumor models
14天前
已采纳
Abstract 1635: OKI-1546 is a selective, orally bioavailable inhibitor of CDK12 that causes tumor regression in multiple preclinical cancer models
16天前
已采纳
KT-253, A Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy Than MDM2 Small Molecule Inhibitors
23天前
已采纳
Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients
24天前
已采纳
Abstract 583: AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via fibroblast activation protein (FAP) mediated cleavage
1个月前
已采纳
皖公网安备34019202002308
